Diaphragmatic Myofascial Release for Hyperkyphotic Subjects

Response of Lung Function, Chest Mobility, and Kyphotic Curve to Diaphragmatic Myofascial Release in Hyperkyphotic Subjects: A Randomized Controlled Trial

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06621667

Enrollment

Registered

2024-10-01

Start date

2024-10-10

Completion date

2024-12-30

Last updated

2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperkyphosis

Brief summary

kyphotic subjects have respiratory disturbances due to weakening of the diaphragm, responsible for inhalation, which lead to abnormalities in respiratory mechanics and abnormal gas exchange, leading to respiratory complications. Myofascial release of the diaphragm is an intervention intended to indirectly stretch the diaphragm muscle fibers to reduce muscle tension, normalize fiber length, and promote the efficiency of muscle contraction. Although diaphragm myofascial release has been used in clinical practice, to the best of the authors' knowledge, the current study is the first research investigating the effect of diaphragmatic myofascial release on lung function, chest mobility and kyphotic curve in hyperkyphotic subjects.

Interventions

OTHERdiaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis

diaphragmatic myofascial release

OTHERtraditional physical therapy exercises for hyperkyphosis

traditional physical therapy exercises for hyperkyphosis

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

* The participant's age ranged from 20 to 40 years. * kyphosis angle 40-50◦ * reporting pain on palpation of the diaphragm

Exclusion criteria

* A history of respiratory diseases, heart disease, vascular disease, central nervous system disorder, psychiatric disorders, hypertension. * History of any trauma or fracture to the thoracic spine. * inflammatory diseases such as rheumatoid arthritis, musculoskeletal problem and neurological deficit * Restrictive respiratory disease, smokers.

Design outcomes

Primary

Measure	Time frame	Description
maximum voluntary ventilation	change from base line at 4 weeks.	the maximum voluntary ventilation will be measured using spirometer

Secondary

Measure	Time frame	Description
Chest expansion	change from base line at 4 weeks.	the chest expansion will be measured using tap measurement
kyphotic angle	change from base line at 4 weeks.	the kyphotic angle will be measured with flexicurve

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026